Nuvalent Expands Leadership in Precision Lung Cancer
CAMBRIDGE, Mass., May 27, 2026 Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on developing precisely targeted cancer therapies, has...
Oncology drug development
Advertisement
Dizal Advances ZEGFROVY for EGFR Lung Cancer
SHANGHAI, China, May 27, 2026 Dizal, a biopharmaceutical company focused on developing targeted oncology therapies, has announced that China’s...
GSK Partners With SBP Group to Expand Hepatitis B Treatment
LONDON, UK – May 11, 2026 GSK plc announced an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group) through...
Innovent Secures Third NMPA Breakthrough Status for IBI363
SAN FRANCISCO and SUZHOU, China, May 10, 2026 Innovent Biologics, Inc. announced that China’s National Medical Products Administration (NMPA)...
Nuvation Bio Expands IBTROZI FDA Lung Cancer Filing
NEW YORK, May 6, 2026 Nuvation Bio Inc., a global oncology-focused biopharmaceutical company, has announced that the U.S. Food...
Advertisements
DualityBio Advances HER2 ADC Toward China Approval
SHANGHAI, China, April 9, 2026 DualityBio has announced that the China National Medical Products Administration (NMPA) has accepted the...
C4 and Roche Expand DAC Cancer Drug Collaboration
WATERTOWN, Mass., April 09, 2026 C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche,...
Zymeworks’ ZW191 Gets FDA Fast Track for Cancer
VANCOUVER, British Columbia, March 30, 2026 Zymeworks Inc. announced that the U.S. FDA has granted Fast Track designation to...
Servier to Acquire Day One Biopharmaceuticals for $2.5B
March 06, 2026 — Suresnes, France & Brisbane, California, USA Global pharmaceutical group Servier and oncology-focused biotech Day One...
Incyte’s Zynyz Approved in EU for Advanced Anal Cancer
March 06, 2026 — Wilmington, Delaware, USA Global biopharmaceutical innovator Incyte has announced that the European Commission has approved...
Advertisement
